- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 11/06 - Antiasthmatics
Patent holdings for IPC class A61P 11/06
Total number of patents in this class: 3928
10-year publication summary
164
|
146
|
119
|
196
|
256
|
257
|
273
|
238
|
196
|
55
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
AstraZeneca AB | 3042 |
146 |
F. Hoffmann-La Roche AG | 7958 |
74 |
Chiesi Farmaceutici S.p.A. | 940 |
68 |
Boehringer Ingelheim International GmbH | 4629 |
63 |
Daiichi Sankyo Company, Limited | 1829 |
49 |
Genentech, Inc. | 3742 |
46 |
Takeda Pharmaceutical Company Limited | 2961 |
36 |
Novartis AG | 11238 |
35 |
Dainippon Sumitomo Pharma Co., Ltd. | 234 |
30 |
Regeneron Pharmaceuticals, Inc. | 3650 |
30 |
Theravance Biopharma R&D IP, LLC | 550 |
27 |
Glaxo Group Limited | 4496 |
26 |
Ono Pharmaceutical Co., Ltd. | 454 |
26 |
Astellas Pharma Inc. | 1145 |
25 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 2912 |
25 |
Bristol-myers Squibb Company | 5080 |
24 |
KYORIN Pharmaceutical Co., Ltd. | 188 |
24 |
The Regents of the University of California | 18943 |
23 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
23 |
Mitsubishi Tanabe Pharma Corporation | 579 |
22 |
Other owners | 3106 |